BDBM163700 N-(5-((4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)-2-methylphenyl)-5-(1-methyl-1H-pyrazol-4-yl)nicotinamide (5)::US10597387, Compound (I-9)

SMILES CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(NC(=O)c4cncc(c4)-c4cnn(C)c4)c3)cc2C(F)(F)F)CC1

InChI Key InChIKey=GZOONDJISKPFEJ-UHFFFAOYSA-N

Data  4 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 163700   

TargetDiscoidin domain-containing receptor 2(Human)
Dana-Farber Cancer Institute

LigandPNGBDBM163700(N-(5-((4-((4-ethylpiperazin-1-yl)methyl)-3-(triflu...)
Affinity DataIC50: 56nMAssay Description:The enzymatic activities SRC are tested in Z'-Lyte assays with ATP concentrations of Km (50 uM)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2016
Entry Details Article
PubMed
TargetProto-oncogene tyrosine-protein kinase Src(Human)
Dana-Farber Cancer Institute

LigandPNGBDBM163700(N-(5-((4-((4-ethylpiperazin-1-yl)methyl)-3-(triflu...)
Affinity DataIC50: 12nMAssay Description:The enzymatic activities SRC are tested in Z'-Lyte assays with ATP concentrations of Km (50 uM)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2016
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM163700(N-(5-((4-((4-ethylpiperazin-1-yl)methyl)-3-(triflu...)
Affinity DataIC50: 25.3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase HCK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM163700(N-(5-((4-((4-ethylpiperazin-1-yl)methyl)-3-(triflu...)
Affinity DataIC50: 2.43nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2020
Entry Details
Go to US Patent